CEL-SCI Co. (NYSE:CVM) Short Interest Update

Key Points

• CEL-SCI Co. experienced a significant increase in short interest, growing by 36.7% in August, with approximately 15.3% of shares short sold.
• CEO Geert R. Kersten increased his ownership of the company by 66.91% after purchasing 29,197 shares valued at nearly $200,000.
• Bank of America Corp DE drastically raised its stake in CEL-SCI by 2,188.2%, now owning approximately 0.60% of the company with a value of $94,000.

CEL-SCI Co. (NYSE:CVM - Get Free Report) saw a large growth in short interest during the month of August. As of August 15th, there was short interest totaling 1,040,000 shares, agrowthof36.7% from the July 31st total of 760,700 shares. Approximately15.3% of the company's shares are short sold. Based on an average daily volume of 804,500 shares, the days-to-cover ratio is currently 1.3 days. Based on an average daily volume of 804,500 shares, the days-to-cover ratio is currently 1.3 days. Approximately15.3% of the company's shares are short sold.

Insider Activity

In other CEL-SCI news, CEO Geert R. Kersten bought 29,197 shares of CEL-SCI stock in a transaction dated Friday, July 25th. The shares were bought at an average price of $6.85 per share, with a total value of $199,999.45. Following the purchase, the chief executive officer owned 72,835 shares of the company's stock, valued at $498,919.75. This trade represents a 66.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 9.93% of the company's stock.

Institutional Trading of CEL-SCI

A hedge fund recently raised its stake in CEL-SCI stock. Bank of America Corp DE lifted its position in CEL-SCI Co. (NYSE:CVM - Free Report) by 2,188.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,981 shares of the company's stock after acquiring an additional 39,190 shares during the period. Bank of America Corp DE owned approximately 0.60% of CEL-SCI worth $94,000 at the end of the most recent quarter. 12.08% of the stock is currently owned by hedge funds and other institutional investors.

CEL-SCI Trading Down 1.3%

Shares of NYSE:CVM traded down $0.14 during mid-day trading on Monday, reaching $10.35. The stock had a trading volume of 205,582 shares, compared to its average volume of 371,205. The firm has a market cap of $71.23 million, a PE ratio of -21.56 and a beta of 0.54. The firm has a 50 day simple moving average of $7.32 and a two-hundred day simple moving average of $6.64. The company has a current ratio of 1.07, a quick ratio of 1.09 and a debt-to-equity ratio of 0.66. CEL-SCI has a twelve month low of $1.98 and a twelve month high of $39.30.

Wall Street Analyst Weigh In

Separately, Wall Street Zen began coverage on shares of CEL-SCI in a research note on Friday, May 16th. They issued a "sell" rating on the stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.